Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,518 total articles
Truist Securities has adjusted its price target for RLI Corp downward to $58 from $62, maintaining a Hold rating as concerns around the company's property underwriting profits weigh on earnings growth expectations. The insurer currently trades near its 52-week low, with recent financial results showing a mixed performance and varied analyst opinion…
TD Cowen has reaffirmed its Buy rating on Roper Industries, valuing the stock at $625 per share, which implies a substantial 53% upside from current trading levels. Despite a notable decline in Roper's stock over the past six months, the firm underscores impressive free cash flow yields exceeding 6%, signaling attractive investment value. The analy…
TD Cowen maintains a Buy rating and a $64 price target on Alaska Air following strong fourth-quarter earnings and robust demand forecasts for 2026. The airline surpassed earnings expectations, lowered operating costs, and continues fleet expansion and technology upgrades to enhance competitiveness. Despite wider-than-expected guidance ranges, the o…
TD Cowen has lowered its price target for Abbott Laboratories following the company's fourth-quarter revenue and earnings misses, accompanied by cautious sales guidance for 2026. While sharing a subdued outlook, TD Cowen retains a Buy rating, citing attractive valuation levels and expected improvements in Diagnostics and Nutrition segments over tim…
TD Cowen has reiterated its Hold rating and set a $50 price target for Intel following an earnings report that met expectations but disappointed in future guidance. The firm expressed reservations about Intel's profitability outlook, tempered by the view that it is premature to dismiss the company’s prospects entirely. Meanwhile, other analysts pre…
TD Cowen has raised its price target for Atlantic Union Bankshares to $46.00 from $45.00, maintaining a Buy rating, following the bank's impressive fourth-quarter 2025 performance. The company's earnings per share and revenue both surpassed expectations, reinforcing confidence in its organic growth potential and financial stability through 2026 and…
Truist Securities increased its price target for defense contractor CACI International to $800 from $735 while maintaining a Buy rating, highlighting expected accelerated growth and solid financial metrics. The stock is trading near its 52-week high, underpinned by robust revenue gains, a competitive software framework, and strategic acquisitions. …
BMO Capital has adjusted its price target for Primo Brands Corp. downward to $35.00 from $39.00 but maintains an Outperform rating, reflecting ongoing efforts to stabilize the business and a slower-than-expected recovery in the customer direct segment. Despite these factors, revenue growth remains robust, with a projected 29% increase in the curren…
Seaport Global Securities has shifted its rating on Axalta Coating Systems from Buy to Neutral due to anticipated softening demand in early 2026. Despite the downgrade, internal cost efficiencies are expected to keep the company on track toward its financial objectives. The prospective merger with AkzoNobel and recent share price trends have influe…
Seaport Global Securities adjusted Quaker Chemical's stock rating from Buy to Neutral due to recent share price increases and signs of weaker demand in key industrial sectors. While the company is expected to secure moderate new business growth and benefits from a forthcoming China facility, challenges in automotive, metals, and industrial markets …
Seaport Global Securities has shifted its rating for Entegris Inc from Buy to Neutral, citing the stock's significant price increase which appears to have already factored in much of the expected earnings growth for 2026. The firm highlights overvaluation concerns based on current valuation multiples and points to obstacles in organic growth during…
Seaport Global Securities has revised its rating on Materion Corporation (NYSE:MTRN) from Buy to Neutral, citing that the current stock price incorporates expected strong earnings growth. The firm highlights continued strength in specific divisions alongside valuation metrics suggesting overextension in price.
Seaport Global Securities has elevated Stepan Company's (NYSE:SCL) stock rating from Neutral to Buy, anticipating improved earnings continuity and margin expansion driven largely by the increased productivity of the Pasadena alkoxylation facility. Despite a recent earnings shortfall and ongoing operational adjustments, the company's strategic initi…
BMO Capital has increased its price target for Halliburton to $39 from $36, while maintaining a Market Perform rating after the company posted strong Q4 2025 earnings. Halliburton's revenue is expected to slightly decline in 2026 before resuming growth in 2027. Other financial institutions issued varying outlooks, reflecting cautious optimism about…
Benchmark has upheld a Buy recommendation and a $15 price target on USA Rare Earth's stock, following the company’s recent updates on its Round Top mine initiative in Texas and its expansion plans in Europe. Despite the stock trading above this price, the current valuation appears elevated relative to Benchmark's assessment. The company’s collabora…
BMO Capital has reaffirmed its Outperform rating on Permian Resources Corporation, setting a $21.00 price target that suggests a significant upside potential based on the current market price. The firm updated its financial estimates, projecting incremental improvements in earnings and operational performance, supported by recent corporate reorgani…
BMO Capital has adjusted its price target for ProLogis to $123 from $119, maintaining a Market Perform rating while highlighting improving earnings and positive industrial market fundamentals. The company reported strong Q4 2025 results, with earnings significantly surpassing expectations. Challenges include high valuation premium and changes in ma…
Benchmark reaffirmed its Buy rating and a $40 price target for CSX following the railroad company’s fourth-quarter earnings release. Despite missing earnings estimates and ongoing challenges in revenue growth, the company’s management projects modest revenue increases and improved operating efficiency in 2026, underpinned by substantial cost-saving…
Benchmark has reaffirmed its Buy rating and $42 price target for IMAX Corporation (NYSE:IMAX) following impressive fourth-quarter results and positive indicators for 2026 box office revenue. Driving momentum is the successful international rollout of "Avatar: Fire and Ash" and the introduction of new releases along with varied content offerings, po…
Seaport Global Securities has revised its outlook on Cleveland-Cliffs (NYSE:CLF), moving the stock rating from Buy to Neutral due to the share price surpassing the firm’s $13 target. Although the company starts 2026 with strengthened fundamentals and market conditions, significant debt and projected negative earnings maintain investor caution. An u…
Benchmark has reaffirmed its Buy rating on Abbott Laboratories with a $145 price target, anticipating a 33% rise from current levels. The healthcare giant posted tepid fourth-quarter results, largely due to softness in its Nutrition Products division, but remains hopeful about recovery driven by contract wins and product launches scheduled for 2026…
BMO Capital has lifted its price target for BrightSpring Health to $46 from $40 while retaining an Outperform rating, citing accelerated expansion in its specialty business and impressive recent financial performance. The stock has experienced substantial gains since its IPO, supported by a strong competitive position in pharmaceutical distribution…
RBC Capital has increased its price objective for GH Research PLC to $40 from the previous $33 while maintaining an Outperform rating, reflecting heightened confidence in the company's GH001 depression treatment. The adjustment comes after engagements at the Psychedelics Symposium and updated drug pricing assumptions parallel to Spravato, further b…
Benchmark has increased its price target for Hub Group from $40 to $50, maintaining a Buy stance. The adjustment centers on a five-year earnings valuation outlook, signaling confidence in Hub Group's long-term profitability amidst current market headwinds such as slowing intermodal volumes and margin compression in brokerage operations. Other firms…
RBC Capital has increased its price target for Northern Trust to $159 from $139, maintaining an Outperform rating following the company's strong fourth-quarter 2025 results. With solid revenue growth, positive operating leverage, and strategic medium-term goals, Northern Trust has shown resilience in profitability. The firm's stable dividend track …
